IN-115314 / Korea Kolmar - LARVOL DELTA

JAK-STAT inhibitory effect of IN-115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine. (PubMed, Br J Pharmacol) - "In summary, this study confirmed IN-115314 JAK-STAT inhibitory effect, along with data on its pharmacokinetics, pharmacodynamics, safety, efficacy and optimal dosage. We anticipate that IN-115314 will be developed as a new therapeutic agent for various diseases involving the JAK-STAT pathway."

Journal • PK/PD data • CD4 • IL6 • JAK1 • JAK2

HK inno.N, this time, challenges a new drug called ’JAK inhibitor’ for atopic dermatitis [Google translation] (Medipharms Today) - "On the 12th, the Ministry of Food and Drug Safety approved the phase 2 clinical trial of HK inno.N's 'IN-115314'. This trial was a randomized, double-blind, placebo-controlled, parallel, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of IN-115314 ointment in adult patients with mild to moderate atopic dermatitis."

New P2 trial • Atopic Dermatitis

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: HK inno.N Corporation

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

"Dec 2, 1986 First participant enrolled in A002 #HIV #ResearchersRock @ACTGNetwork @WCM_ID @joseph_eron @6dm4 @MorenikeGO @MARTHOLANAH @Flatmi @EmoryCFAR @rstrange_dc @AwesomeJonesLab @REACHforthecure @TheNixonLab @HOPEforHIVCure https://t.co/pv7Oxt4KlI" (@YvesGebhardt)

Human Immunodeficiency Virus • Infectious Disease

A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: HK inno.N Corporation

Clinical • New P1 trial

[VIRTUAL] PRECLINICAL CHARACTERIZATION OF CJ-15314, A HIGHLY SELECTIVE JAK1 INHIBITOR, FOR THE TREATMENT OF AUTOIMMUNE DISEASES (EULAR 2020) - "Tofacitinib, oral Pan-JAK inhibitor, demonstrated efficacy in RA patients, but its widespread use is limited by safety issues...Accordingly, in human whole blood assays, CJ-15314 is 11 fold more potent against IL-6 induced pSTAT1 inhibition through JAK1 (IC50 value: 70 nM) than GM-CSF-induced pSTAT5 inhibition (JAK2) whereas baricitinib and filgotinib exhibited only 2 fold and 7 fold respectively... CJ-15314 is a highly selective JAK1 inhibitor, demonstrates robust efficacy in RA animal model and is good candidate for further development for inflammatory diseases. * CJ-15314 is currently conducting a phase I trial in south Korea."

Preclinical • Hematological Disorders • Immunology • Rheumatology • Thrombocytopenia • CXCL8 • IL6 • JAK2 • JAK3

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects (clinicaltrials.gov) - P1; N=55; Recruiting; Sponsor: CJ HealthCare Corporation

Clinical • New P1 trial